ForPatients
by Roche

Breast Cancer

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Trial Status	**Trial Runs In**	**Trial Identifier**
Completed	1 Countries	NCT02613208 ROC-BEV-2015-01 ML29756

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, observational, prospective study will identify a powerful and easy predictive/prognostic marker to use with participants under bevacizumab.

Hoffmann-La Roche
Sponsor

NCT02613208 ROC-BEV-2015-01 ML29756
Trial Identifiers

Eligibility Criteria:

Gender	**Age**	**Healthy Volunteers**
All	>=18 Years	No